RougeTx Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $58M

  • Investors
  • 11

RougeTx General Information

Description

Developer of small-molecule therapies designed to restore vascular stability. The company utilizes a proprietary platform to identify treatment opportunities in diseases driven by vascular instability, focusing on small-molecule therapies that restore vascular integrity by targeting pericyte dysfunction and stabilizing fragile blood vessels through pericyte attachment, enabling the healthcare sector to access disease-modifying treatments for vascular diseases.

Contact Information

Website
www.rougetx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Gooimeer 2-35
  • 1411 DC Naarden
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Gooimeer 2-35
  • 1411 DC Naarden
  • Netherlands

RougeTx Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RougeTx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A) 06-Oct-2026 $58M Completed Generating Revenue
2. Seed Round 01-Jan-2024 Completed Stealth
1. University Spin-Out 01-Jan-2021 Completed Stealth
To view RougeTx’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

RougeTx Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angelini Ventures Corporate Venture Capital Minority
Aurea (Business/Productivity Software) PE-Backed Company Minority
Epidarex Capital Venture Capital Minority
Kerna Ventures Venture Capital Minority
Kurma Partners Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

RougeTx FAQs

  • When was RougeTx founded?

    RougeTx was founded in 2021.

  • Where is RougeTx headquartered?

    RougeTx is headquartered in Naarden, Netherlands.

  • What industry is RougeTx in?

    RougeTx’s primary industry is Drug Discovery.

  • Is RougeTx a private or public company?

    RougeTx is a Private company.

  • What is RougeTx’s current revenue?

    The current revenue for RougeTx is .

  • How much funding has RougeTx raised over time?

    RougeTx has raised $58M.

  • Who are RougeTx’s investors?

    Angelini Ventures, Aurea (Business/Productivity Software), Epidarex Capital, Kerna Ventures, and Kurma Partners are 5 of 11 investors who have invested in RougeTx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process